[The results of clinical trials and the prospects of using the Soviet preparation of human recombinant interferon alpha-2 (reaferon) in medical practice]. 1990

Iu T Kalinin, and A A Vorob'ev, and V V Bumialis, and L A Denisov, and V V Parfenov, and A V Klenova, and A A Ianulaĭtis, and F I Ershov, and V I Marchenko, and V V Malinovskaia

The results of the clinical trials of human recombinant interferon alpha-2 (reaferon) make it possible to come to the conclusion that the preparation is well-tolerated and produces a pronounced therapeutic effect in a number of viral and oncological diseases. The Pharmacological Committee of the USSR has recommended reaferon for use in acute hepatitis B, hairy cell leukemia, renal cancer at stage IV, disseminated sclerosis, ocular herpes. The use of reaferon has been found to be promising in the treatment of papillomatosis of the larynx, Kaposi's sarcoma, mycosis fungoides, chronic myeloleukemia.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500
D014586 USSR A country located from the Baltic and Black seas to the Pacific Ocean and, for a time including 15 Soviet Socialist Republics. The capital was Moscow. Soviet Union,Union of Soviet Socialist Republics
D016898 Interferon-alpha One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways. Interferon Alfa,Interferon, Leukocyte,Interferon, Lymphoblast,alpha-Interferon,IFN-alpha D,IFN-alpha5,Interferon alpha-1,Interferon alpha-17,Interferon alpha-4,Interferon alpha-5,Interferon alpha-7,Interferon alpha-88,Interferon alpha-J,Interferon alpha-T,Interferon alpha4,Interferon alpha5,Interferon, Lymphoblastoid,Interferon, alpha,LeIF I,LeIF J,Leif D,IFN alpha D,IFN alpha5,Interferon alpha,Interferon alpha 1,Interferon alpha 17,Interferon alpha 4,Interferon alpha 5,Interferon alpha 7,Interferon alpha 88,Interferon alpha J,Interferon alpha T,Leukocyte Interferon,Lymphoblast Interferon,Lymphoblastoid Interferon,alpha Interferon

Related Publications

Iu T Kalinin, and A A Vorob'ev, and V V Bumialis, and L A Denisov, and V V Parfenov, and A V Klenova, and A A Ianulaĭtis, and F I Ershov, and V I Marchenko, and V V Malinovskaia
January 1989, Voprosy virusologii,
Iu T Kalinin, and A A Vorob'ev, and V V Bumialis, and L A Denisov, and V V Parfenov, and A V Klenova, and A A Ianulaĭtis, and F I Ershov, and V I Marchenko, and V V Malinovskaia
January 1989, Voprosy virusologii,
Iu T Kalinin, and A A Vorob'ev, and V V Bumialis, and L A Denisov, and V V Parfenov, and A V Klenova, and A A Ianulaĭtis, and F I Ershov, and V I Marchenko, and V V Malinovskaia
January 1988, Voprosy virusologii,
Iu T Kalinin, and A A Vorob'ev, and V V Bumialis, and L A Denisov, and V V Parfenov, and A V Klenova, and A A Ianulaĭtis, and F I Ershov, and V I Marchenko, and V V Malinovskaia
July 1989, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
Iu T Kalinin, and A A Vorob'ev, and V V Bumialis, and L A Denisov, and V V Parfenov, and A V Klenova, and A A Ianulaĭtis, and F I Ershov, and V I Marchenko, and V V Malinovskaia
January 1989, Voprosy virusologii,
Iu T Kalinin, and A A Vorob'ev, and V V Bumialis, and L A Denisov, and V V Parfenov, and A V Klenova, and A A Ianulaĭtis, and F I Ershov, and V I Marchenko, and V V Malinovskaia
January 1990, Terapevticheskii arkhiv,
Iu T Kalinin, and A A Vorob'ev, and V V Bumialis, and L A Denisov, and V V Parfenov, and A V Klenova, and A A Ianulaĭtis, and F I Ershov, and V I Marchenko, and V V Malinovskaia
July 1988, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
Iu T Kalinin, and A A Vorob'ev, and V V Bumialis, and L A Denisov, and V V Parfenov, and A V Klenova, and A A Ianulaĭtis, and F I Ershov, and V I Marchenko, and V V Malinovskaia
February 1987, Leukemia,
Iu T Kalinin, and A A Vorob'ev, and V V Bumialis, and L A Denisov, and V V Parfenov, and A V Klenova, and A A Ianulaĭtis, and F I Ershov, and V I Marchenko, and V V Malinovskaia
January 1992, Immunology series,
Iu T Kalinin, and A A Vorob'ev, and V V Bumialis, and L A Denisov, and V V Parfenov, and A V Klenova, and A A Ianulaĭtis, and F I Ershov, and V I Marchenko, and V V Malinovskaia
January 1986, The American journal of pediatric hematology/oncology,
Copied contents to your clipboard!